Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

S-adenosylmethionine (SAMe)

S-Adenosyl-L-Methionine (SAMe) · also known as SAMe, Ademetionine, Ademetionine

SAMe is an important methyl donor for many methyltransferases. Oral doses can raise SAM levels in the blood, but the effect on methylation in tissues varies between people. Evidence that it raises liver glutathione is also inconsistent.

Typical dose: The usual dose is 200–800 mg/day, most often taken in the morning or before lunch. Enteric-coated tablets should be swallowed whole, not chewed.
Absorption and forms: The SAMe molecule is unstable and breaks down easily in stomach acid. Enteric-coated formulations reduce this loss. Stability and absorption also differ between salt forms, so choose a reputable product.

Clinical uses and human evidence

Low mood

Mixed resultsGrade B · Moderate evidence
Studies (3)
  1. Limveeraprajak 2024 · Prog Neuropsychopharmacol Biol Psychiatry · Meta-analysis · n=2183 — Efficacy and acceptability of S-adenosyl-L-methionine (SAMe) for depressed patients: A systematic review and meta- analysis
  2. Sarris 2020 · Psychopharmacology (Berl) · RCT · n=49 — S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial
  3. Mischoulon 2014 · J Clin Psychiatry · RCT · n=189 — A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder

Osteoarthritis pain

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Rutjes 2009 · Cochrane Database Syst Rev · Meta-analysis · n=656 — S-Adenosylmethionine for osteoarthritis of the knee or hip

Fatty liver and liver enzymes

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Medici 2011 · Alcohol Clin Exp Res · RCT · n=37 — S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial

All-cause mortality risk

Mixed resultsGrade B · Moderate evidence
Studies (1)
  1. Mato 1999 · J Hepatol · RCT · n=123 — S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial

Mechanisms of action

One-carbon cycle methyl donor (SAMe) regeneration and Hcy clearance

★★★★☆Mechanism evidence: grade A

SAMe is an important donor for many methyltransferases. Studies in people with liver disease and in healthy people both show that oral SAMe raises serum or plasma SAM. That does not mean methylation flux rises markedly in every tissue, or that SAMe directly promotes homocysteine remethylation.

References (2)
  1. Medici et al. 2011 · RCT in 37 patients with liver disease: with 1.2 g/day orally, serum SAM was higher than in the placebo group during follow-up
  2. Cameron et al. 2020 · Pharmacokinetic study in healthy people: 400–800 mg taken orally can increase plasma SAM exposure, and exposure differs between formulations

Substrate and cofactor supply for glutathione (GSH) synthesis

★★★☆☆Mechanism evidence: grade BSecondary target

After donating its methyl group, SAMe becomes homocysteine, which the transsulfuration pathway converts to cysteine, indirectly supplying raw material for glutathione synthesis. One small controlled study found higher glutathione in liver biopsies, but another randomized trial found no significant change in serum glutathione.

References (2)
  1. Vendemiale et al. 1989 · Small controlled human study: in patients with liver disease, glutathione in liver biopsies rose after 1.2 g/day orally for 6 months
  2. RCT of SAMe in cirrhosis · No significant change in serum glutathione was observed

Safety and drug interactions

Absolutely contraindicated in bipolar disorder, where it can trigger an extremely severe switch into mania. If it is combined with prescription antidepressants that act on serotonin (5-HT), a physician must monitor closely.

Serotonin excess risk

Involved in making monoamine neurotransmitters. Each of these raises serotonin levels in the brain. Taking two or more together carries a risk of serotonin syndrome, which causes agitation, sweating, a fast heartbeat, muscle twitching and fever. In severe cases it can be life-threatening.

With SSRIs, SNRIs and other serotonergic drugs High risk

Sertraline, fluoxetine, paroxetine, venlafaxine, duloxetine, tramadol, triptans (migraine drugs)

May enhance the drug’s effects and trigger serotonin syndrome. Use only under a doctor’s supervision.

With MAO inhibitors High risk

Phenelzine, selegiline, rasagiline, linezolid

May trigger serotonin syndrome.

Open in the interactive app ›